Covidien is looking to sell its pharmaceuticals unit for as much as $4 billion, a source familiar with the situation said on Tuesday.
JPMorgan Chase is advising Covidien on the matter, said the source, who declined to be named because the
Covidien, a leading provider of healthcare products, said it has completed the sale of its 'sleep therapy' continuous positive airway pressure (CPAP) and bi-level products to PH Invest, a privately held company located in Luxembourg.
Covidien, a Dublin-based global provider of healthcare products, has completed its tender offer to purchase all of the outstanding shares of common stock of ev3, a leading developer and marketer of endovascular devices.
The tender offer wa